AST Spacemobile Just Moved Its Commercial Launch Target to 2027. Is That Bad News for Its Stock?

AST SpaceMobile pushed back its 45-satellite deployment target from late 2026 to early 2027, contributing to the stock’s drop from a record $133.09 (May 28, 2026) to the low $60s. While the delay is described as disappointing, AST cites a $1.3B backlog, work with 60+ carriers covering 3B+ subscribers, and a long-term plan for at least 248 satellites. Analysts still expect revenue to rise from $71M (2025) to $1.73B (2028) with EBITDA turning positive in the final two years, though shares are noted as expensive at ~33x next year’s sales on a ~$21B enterprise value.

Analysis

The market is not just punishing a schedule slip; it is repricing the probability of a clean, uninterrupted buildout. For ASTS, valuation is still anchored to a terminal network story, but near-term equity performance is now driven by whether the company can prove launch cadence and translate partnerships into funded revenue, not by backlog headlines. That shift usually compresses multiples first and forces estimate cuts later, so the next leg is more likely to come from technical de-risking than from fundamentals.

The bigger second-order risk is financing, not demand. A delayed constellation pushes out operating leverage while launch and manufacturing burn continue, which raises the odds of dilution or structured capital before EBITDA inflects. That matters for per-share value more than the revenue bridge, and it creates a window where incumbents like T and VZ can keep monetizing coverage expansion without taking development risk, while satellite peers such as IRDM and GSAT benefit from investor skepticism around unproven economics.

Contrarian take: the move may be partially overdone if the market is treating a one-step delay as a broken thesis. The real falsifier is not the date shift itself but a failure to restore cadence over the next 1-2 quarters or any sign of incremental financing stress. If ASTS can post consecutive successful deployments and reaffirm commercial conversion, the stock can re-rate quickly; if not, it transitions from a growth story to a capital-intensive project, which is a very different multiple.

Key Decisions for Investors

• Stay underweight ASTS for the next 1-3 months; do not chase rebounds until the company proves two consecutive successful launches and reaffirms the constellation timetable. Risk to this stance is a fast rerating if execution normalizes, but downside remains asymmetric if another slip hits.
• Use tactical options, not spot equity, for bearish exposure: sell ASTS call spreads or buy put spreads into strength over the next 4-8 weeks. The setup favors premium selling because the stock still embeds a lot of perfect-execution assumptions.
• Prefer T and VZ over ASTS for satellite-enabled coverage exposure over 6-18 months. The carriers capture optionality with much lower execution and financing risk, while ASTS remains the higher-beta way to express the theme.
• Set a hard alert on any ASTS equity raise, convert issuance, or launch-insurance disclosure. That would be a stronger bearish catalyst than the schedule delay itself and would justify adding to shorts or hedges.